XOMA: Now is at a good entry point at $1.42. The f
Post# of 22708
![Avatar](/images/ProfileImages/930245149_8857_Penguins.jpg)
Novo Nordisk A/S has agreed to buy the global rights to Xoma Corp.'s Type 2 diabetes treatment in a deal worth up to $295 million.
The price tag includes a $5 million upfront payment to Xoma and up to $290 million in milestones. Xoma also is eligible for royalties on product sales.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)